Ensysce Biosciences Investor Relations Material
Latest events
Q4 2023
Ensysce Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Ensysce Biosciences Inc
Access all reports
Ensysce Biosciences Inc. is a clinical-stage pharmaceutical company focused on developing innovative drug delivery technologies aimed at improving safety in pain management. The company is known for its development of two proprietary platforms: the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR). These platforms are designed to reduce the risks associated with prescription opioid misuse, abuse, and overdose by enhancing the safety of oral drug delivery. Ensysce's product pipeline includes prodrug technologies that aim to provide effective pain relief while mitigating the potential for abuse and overdose. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ under the ticker symbol ENSC.
Latest articles
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
Ticker symbol
Country
đșđž United States